E. Gane

O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY

Nezam H. Afdhal, Greg Everson, José Luís Calleja et al. · Journal of Hepatology · 2014 · 61 citations

Hepatology, Viral Hepatitis, Liver Physiology +6

Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial

Ching‐Lung Lai, E. Gane, Y‐F Liaw et al. · 2005 · 39 citations

First-year Results, Hepatology, Viral Hepatitis +7

P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial

Paul Y. Kwo, E. Gane, Cheng‐Yuan Peng et al. · Journal of Hepatology · 2015 · 38 citations

Viral Hepatitis, Antiviral Drug Development, Antiviral Therapy +8

50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B

G.K.K. Lau, Teerha Piratvisuth, K.X. Luo et al. · Journal of Hepatology · 2006 · 33 citations · Full text

Hepatology, Viral Hepatitis, Year Post-treatment +7

2003 ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS

E. Gane, Graham R. Foster, J Cianciara et al. · Journal of Hepatology · 2010 · 16 citations

Viral Hepatitis, Antiviral Activity, Pharmacology +9